PASG — Passage BIO, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1787297 ·
Last close
$4.68
Market Cap
$15.04M
52W High
$20.00
52W Low
$3.29
ADV30
24,838
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,216,000 | -7,821,000 | 25,175,000 | 24,155,000 | 20,719,000 |
| Mar 2026 | 0 | — | -8,880,000 | -7,559,000 | 36,462,000 | 33,336,000 | 24,710,000 |
| Dec 2025 | 0 | — | -10,340,000 | -12,983,000 | 62,281,000 | 46,303,000 | 43,526,000 |
| Sep 2025 | 0 | — | -8,655,000 | -7,749,000 | 74,160,000 | 52,773,000 | 43,040,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,649,000
Investing CF
$605,000
Financing CF
$23,000
CapEx
$-14,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-712,316,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-38,209,000
Pretax Income TTM
$-37,676,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -43,151,000 | -45,522,000 | 62,281,000 | 43,526,000 | 18,755,000 | -31,509,000 |
| Dec 2024 | 0 | -65,167,000 | -64,767,000 | 102,412,000 | 41,151,000 | 61,261,000 | -47,956,000 |
| Dec 2023 | 0 | -102,999,000 | -102,062,000 | 150,545,000 | 39,262,000 | 111,283,000 | -78,264,000 |
| Dec 2022 | 0 | -135,394,000 | -136,125,000 | 243,549,000 | 42,183,000 | 201,366,000 | -118,210,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCDA | BioCardia, Inc. | $15.74M | $1.04 | — |
| ZIVO | Zivo Bioscience, Inc. | $13.91M | $3.30 | — |
| CKDXF | Opthea Ltd | $13.68M | $0.01 | — |
| INAB | IN8BIO, INC. | $12.22M | $1.24 | — |
| DYAI | DYADIC INTERNATIONAL INC | $18.63M | $0.47 | — |
News headlines (Yahoo Finance, 1h cache)
Remix to go public in reverse merger with once high-flying Passage Bio
2026-06-25 10:55 · Yahoo
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?
2026-06-24 22:47 · Yahoo
Passage Bio and Remix Therapeutics Announce Merger Agreement
2026-06-24 20:05 · Yahoo
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
2026-04-21 18:20 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-21 19:57 · Yahoo
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
2026-04-20 11:00 · Yahoo
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
2026-04-21 15:46 · Yahoo
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
2026-06-25 01:43 · Yahoo
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
2026-05-20 12:35 · Yahoo
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
2026-03-03 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.